English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib

MPS-Authors
/persons/resource/persons147352

Zander,  Thomas
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147249

Neumaier,  Bernd
Radiochemistry, Scientific Services and Development, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

/persons/resource/persons147154

Dietlein,  Markus
Translational Neurocircuitry, Research Groups, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Kahraman, D., Holstein, A., Scheffler, M., Zander, T., Nogova, L., Lammertsma, A. A., et al. (2012). Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib. Clinical Nuclear Medicine, 37(11), 1058-1064. doi:10.1097/RLU.0b013e3182639747.


Cite as: https://hdl.handle.net/11858/00-001M-0000-0026-DA7A-7
Abstract
Copyright © 2012 by Lippincott Williams & Wilkins.